Hikma Pharmaceuticals will add Surendera Tyagi as Group Chief Scientific Officer and Global Head of Research and Development, who will will focus on the non-injectables business during the first year and will become a member of Hikma’s Executive Committee, the company said in a media release Monday.
Saïd Darwazah, the Chairman and Chief Executive Officer, said that Tyagi is an outstanding scientist with a proven track record of leading research and development in some of the world’s largest and most successful pharmaceutical organizations. “Research and Innovation is one of our five pillars for growth and the appointment of Surendera is a significant step forward in executing on this strategy. We are very excited for Surendera to be joining us and accelerating our ability to develop novel ways to improve the health of people around the world,” he added.
Dr Tyagi joins from Fresenius Kabi, where he most recently led their US Innovation & Development Center. Also, Dr Tyagi has been an active member of the Association for Affordable Medicines, and participated in GDUFA II negotiations with the FDA.
Dr Tyagi commented: “Hikma’s track record of delivering affordable, quality medicines to people who need them is a purpose that I share. I look forward to accelerating their R&D efforts by advancing and expanding their pipeline, leveraging Hikma’s highly experienced and talented R&D team.”
Image: Saïd Darwazah, the Chairman and Chief Executive Officer, Hikma